Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. (INDP) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · INDP · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
2
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Indaptus Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
INDP insider buying and selling by quarter
INDP insider selling · INDP insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · INDP ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
INDP executive sell shares · INDP board member insider trading · INDP insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jan 20, 2026 | Ben-Tzvi Avraham Director | Award | 25,000 | — | Form 4 |
| Dec 22, 2025 | Sassi Nir CFO | Award | 26,758 | $54K | Form 4 |
| Dec 22, 2025 | Meckler Jeffrey A Co-Chief Executive Officer · Director | Award | 216,617 | $440K | Form 4 |
| Dec 22, 2025 | Newman Michael James CSO and Director | Award | 52,204 | $106K | Form 4 |
| Dec 22, 2025 | Linscott Walt Addison COO | Award | 54,421 | $110K | Form 4 |
| Jul 27, 2025 | Meckler Jeffrey A CEO · Director | Award | 6,068 | $50K | Form 4 |
| Aug 14, 2023 | Anderson Glen R. 10 percent owner | Purchase | 23,934 | $56K | Form 4 |
| Aug 11, 2023 | Anderson Glen R. 10 percent owner | Purchase | 35,064 | $74K | Form 4 |
| Aug 10, 2023 | Anderson Glen R. 10 percent owner | Purchase | 44,354 | $86K | Form 4 |
| Dec 1, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 500 | $935 | Form 4 |
| Nov 22, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 500 | $915 | Form 4 |
| Mar 2, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 50 | $205 | Form 4 |
| Jan 31, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 100 | $465 | Form 4 |
| Jan 31, 2022 | Newman Michael James CSO and Director | Sale | 5,870 | $29K | Form 4 |
| Feb 1, 2022 | Newman Michael James CSO and Director | Sale | 14,130 | $71K | Form 4 |
| Nov 18, 2021 | Meckler Jeffrey A CEO and Director | Purchase | 11,187 | $65K | Form 4 |
Meckler Jeffrey A
Co-Chief Executive Officer · Director
Date
Dec 22
Shares
216,617
Price
$2.03
Value
$440K
Newman Michael James
CSO and Director
Date
Dec 22
Shares
52,204
Price
$2.03
Value
$106K
Anderson Glen R.
10 percent owner
Date
Aug 14
Shares
23,934
Price
$2.34
Value
$56K
Anderson Glen R.
10 percent owner
Date
Aug 11
Shares
35,064
Price
$2.12
Value
$74K
Anderson Glen R.
10 percent owner
Date
Aug 10
Shares
44,354
Price
$1.94
Value
$86K
Litchev Boyan Vesselinov
Chief Medical Officer
Date
Dec 1
Shares
500
Price
$1.87
Value
$935
Litchev Boyan Vesselinov
Chief Medical Officer
Date
Nov 22
Shares
500
Price
$1.83
Value
$915
Litchev Boyan Vesselinov
Chief Medical Officer
Date
Mar 2
Shares
50
Price
$4.09
Value
$205
Litchev Boyan Vesselinov
Chief Medical Officer
Date
Jan 31
Shares
100
Price
$4.65
Value
$465
Newman Michael James
CSO and Director
Date
Jan 31
Shares
5,870
Price
$5.00
Value
$29K
Newman Michael James
CSO and Director
Date
Feb 1
Shares
14,130
Price
$5.00
Value
$71K
Meckler Jeffrey A
CEO and Director
Date
Nov 18
Shares
11,187
Price
$5.82
Value
$65K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About INDP insider trading
INDP insider trades
Indaptus Therapeutics, Inc. (INDP) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Meckler Jeffrey A (Co-Chief Executive Officer · Director), Ben-Tzvi Avraham (Director), Sassi Nir (CFO). Over the past 12 months, 5 insiders have filed transactions with the SEC. INDP insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Indaptus Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
INDP insider trading · 5 questionsThe insiders of Indaptus Therapeutics, Inc. (INDP) include executives and directors such as Meckler Jeffrey A (Co-Chief Executive Officer · Director), Ben-Tzvi Avraham (Director), Sassi Nir (CFO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026